Tomasz Szczudlo

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan et al. · The Lancet Oncology · 2016 · 467 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector et al. · Blood · 2014 · 96 citations

Expanding Nilotinib Access in Clinical Trials (ENACT)

Franck E. Nicolini, Anna Turkina, Zhixiang Shen et al. · Cancer · 2011 · 68 citations · Full text

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala et al. · The Lancet Haematology · 2016 · 40 citations · Full text

Chronic Phase, Open-label Trial, Hematological Malignancy +11

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

Franck E. Nicolini, Tamás Masszi, Zhixiang Shen et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 36 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +14